(Q37529843)

20 August 2017

1 reference

title

Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis (English)

1 reference

20 August 2017

1 reference

2

Ayalew Tefferi

1 reference

20 August 2017

Ruben A Mesa

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Emerging Drugs

20 August 2017

published in

1 reference

20 August 2017

volume

14

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

471-479

1 reference

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Unexplained pulmonary hypertension in chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Nuclear translocation of urokinase-type plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

5-Azacitidine has limited therapeutic activity in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Platelet count in essential thrombocythemia: the more the better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903066809

10.1517/14728210903066809

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference